RLMD · Relmada Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $26.88M | $46.18M | $54.81M | $113.32M | $90.62M | $35.97M |
| SG&A | $32.22M | $37.72M | $48.89M | $47.93M | $35.08M | $24.87M |
| Total Operating Expenses | $59.10M | $83.89M | $103.70M | $161.25M | $125.70M | $60.84M |
| D&A | - | - | - | - | $1.3K | $3.8K |
| Operating Income | ($59.10M) | ($83.89M) | ($103.70M) | ($161.25M) | ($125.70M) | ($60.84M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($57.39M) | ($79.98M) | ($98.79M) | ($157.04M) | ($125.75M) | ($59.46M) |
| EPS - Basic | ($1.45) | ($2.65) | ($3.28) | ($7.16) | - | - |
| EPS - Diluted | ($1.45) | ($2.65) | ($3.28) | ($5.30) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.50M | $3.86M | $4.09M | $44.44M | - | $2.50M |
| Accounts Receivable | - | - | - | $512.4K | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $1.57M | $4.13M | $3.51M | $5.26M | $11.19M | $8.35M |
| Current Assets | $93.98M | $45.80M | $97.51M | $152.87M | $223.30M | $118.07M |
| Total Assets | $94.00M | $45.82M | $97.55M | $152.91M | $223.33M | $118.19M |
| Current Liabilities | $6.43M | $10.29M | $12.19M | $12.47M | $15.06M | $12.60M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $7.49M | $10.30M | $12.19M | $12.47M | $15.06M | $12.60M |
| Stockholders' Equity | $86.51M | $35.52M | $85.36M | $140.44M | $208.26M | $105.58M |
| Retained Earnings | ($698.27M) | ($640.88M) | ($560.90M) | ($462.11M) | ($305.07M) | ($179.32M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($45.79M) | ($51.76M) | ($51.66M) | ($103.80M) | ($91.87M) | ($27.81M) |
| Investing Cash Flow | ($48.14M) | $51.56M | $50.45M | $19.73M | ($54.12M) | ($34.45M) |
| Financing Cash Flow | $93.56M | ($40.3K) | ($98.5K) | $45.02M | $187.94M | $28.47M |
| CapEx | - | - | - | - | - | $182.05M |
| Free Cash Flow | - | - | - | - | - | ($209.86M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | 3.53 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -61.0% | -174.6% | -101.3% | -102.7% | -56.3% | -50.3% |
| Return on equity | -66.3% | -225.2% | -115.7% | -111.8% | -60.4% | -56.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 14.62 | 4.45 | 8.00 | 12.26 | 14.83 | 9.37 |
| Quick ratio | 14.62 | 4.45 | 8.00 | 12.26 | 14.83 | 9.37 |
| Cash ratio | 0.54 | 0.37 | 0.34 | 3.56 | - | 0.20 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.09 | 1.29 | 1.14 | 1.09 | 1.07 | 1.12 |
| Liabilities / Assets | 0.08 | 0.22 | 0.13 | 0.08 | 0.07 | 0.11 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 2.2x | 0.4x | 1.5x | 0.7x | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 29.6% | 19.1% | 35.7% | -28.3% | -106.6% | -378.0% |
| Net income growth (YoY) | 28.3% | 19.0% | 37.1% | -24.9% | -111.5% | -243.3% |
| EPS growth (YoY) | 45.3% | 19.2% | 38.1% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 143.5% | -58.4% | -39.2% | -32.6% | 97.3% | -8.7% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing RELMADA THERAPEUTICS against the 5 most active filers in the same SIC group.